{"id":"815455df5d25","type":"article","url":"https://hartvaat.nl/2026/03/25/glp-1-agonisten-en-sglt2-remmers-in-de-praktijk-bescherming-van-hart-en-nieren-v/","title":"GLP-1-agonisten en SGLT2-remmers in de praktijk: bescherming van hart en nieren voorbij diabetes","title_en":"Managing glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in clinical practice","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["canagliflozine","cardiorenal-behandelstrategie","diabetes-en-hart","diabetes-type-1","diabetes-type-2","empagliflozine","glp1-agonisten","glp1-semaglutide-cardiovasculair","liraglutide","obesitas","orforglipron","semaglutide","sglt2-remmers","tirzepatide"],"journal":"Heart","doi":"http://heart.bmj.com/cgi/content/short/112/8/422?rss=1","source_url":"https://doi.org/http://heart.bmj.com/cgi/content/short/112/8/422?rss=1","authors":["Dalpiaz","H.","Masi","S.","Piludu","S.","Agnoletti","D.","Piani","F.","Fiorini","G.","Borghi","C."],"significance":6,"published":"2026-03-25","source_date":"2026-03-25","image":"https://hartvaat.nl/global/img/2ea89016db5e.webp","kennis":["https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/","https://hartvaat.nl/kennis/cardiometabool/sglt2-remmers-bij-diabetes-hartaandoeningen/"],"congress":"","summary_en":"The obesity epidemic has heightened the impact of cardiometabolic risk factors on cardiovascular and kidney disease. GLP-1 receptor agonists (GLP-1RAs) and SGLT2 inhibitors (SGLT2is), originally developed for type 2 diabetes, reduce cardiovascular and renal risk in randomised trials. SGLT2is are the first class proven to improve prognosis in heart failure with preserved ejection fraction (HFpEF), and evidence is accumulating that GLP-1RAs may also help there. Notably, the benefits are independent of diabetes status and baseline renal function. This practice-oriented review discusses how to use these drugs in everyday care for patients at high cardiovascular and renal risk, in line with evolving guidelines.","created":"2026-07-03T10:32:21Z","updated":"2026-07-03T13:31:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"De obesitas-epidemie heeft de impact van cardiometabole risicofactoren op hart- en nierziekten vergroot. GLP-1-receptoragonisten (GLP-1RA) en SGLT2-remmers (SGLT2i), oorspronkelijk ontwikkeld voor diabetes type 2, verminderen in gerandomiseerde trials het risico op cardiovasculaire en renale ziekten. SGLT2i zijn de eerste klasse die de prognose verbetert bij hartfalen met behouden ejectiefractie (HFpEF), en er komt steeds meer bewijs dat ook GLP-1RA daar gunstig zijn. Opvallend is dat de voordelen onafhankelijk zijn van de diabetesstatus en de uitgangsnierfunctie. Dit praktijkgerichte overzicht bespreekt hoe deze middelen in de dagelijkse zorg kunnen worden ingezet bij patiënten met een hoog cardiovasculair en renaal risico, in lijn met de zich ontwikkelende richtlijnen.","abstract_original":"<p>The obesity epidemic has significantly heightened the impact of cardiometabolic risk factors on the global burden of cardiovascular and kidney diseases. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is), originally developed for type 2 diabetes treatment, have demonstrated in randomised controlled trials their ability to reduce the risk of cardiovascular and kidney diseases. This has led to substantial improvements in patient outcomes. SGLT2i, in particular, are the first class of drugs proven to improve the prognosis of patients with heart failure with preserved ejection fraction, and evidence is accumulating to suggest that also GLP-1RA might be beneficial in these patients. Remarkably, the benefits of GLP-1RA and SGLT2i are independent of type 2 diabetes status or baseline renal function. The critical role of these drug classes in managing high cardiovascular risk patients is increasingly acknowledged in guidelines, which"}